Voyager Therapeutics Inc. (VYGR) Stock Rating Upgraded by Zacks Investment Research
Zacks Investment Research upgraded shares of Voyager Therapeutics Inc. (NASDAQ:VYGR) from a hold rating to a buy rating in a research note published on Wednesday. Zacks Investment Research currently has $13.00 price objective on the stock.
According to Zacks, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
A number of other research analysts also recently weighed in on the stock. Wedbush reissued an outperform rating and set a $36.00 target price on shares of Voyager Therapeutics in a research report on Thursday, August 11th. Piper Jaffray Cos. set a $37.00 target price on shares of Voyager Therapeutics and gave the company a buy rating in a research report on Thursday, August 11th. Stifel Nicolaus began coverage on shares of Voyager Therapeutics in a research report on Thursday, July 14th. They set a buy rating and a $33.00 target price for the company. Finally, Cowen and Company reissued a buy rating on shares of Voyager Therapeutics in a research report on Wednesday, June 22nd. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Voyager Therapeutics presently has an average rating of Buy and a consensus price target of $26.80.
Voyager Therapeutics (NASDAQ:VYGR) opened at 11.06 on Wednesday. The company’s market capitalization is $295.61 million. The company has a 50-day moving average of $12.63 and a 200-day moving average of $12.79. Voyager Therapeutics has a 52 week low of $8.12 and a 52 week high of $30.54.
Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by $0.03. Voyager Therapeutics had a negative return on equity of 25.13% and a negative net margin of 150.47%. On average, equities research analysts anticipate that Voyager Therapeutics will post ($1.53) EPS for the current year.
Several hedge funds have recently made changes to their positions in VYGR. State Street Corp boosted its stake in shares of Voyager Therapeutics by 26.0% in the first quarter. State Street Corp now owns 57,705 shares of the company’s stock worth $502,000 after buying an additional 11,900 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Voyager Therapeutics by 19.3% in the first quarter. Geode Capital Management LLC now owns 52,472 shares of the company’s stock worth $458,000 after buying an additional 8,488 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Voyager Therapeutics during the first quarter worth approximately $873,000. Strs Ohio boosted its stake in shares of Voyager Therapeutics by 531.6% in the second quarter. Strs Ohio now owns 12,000 shares of the company’s stock worth $131,000 after buying an additional 10,100 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Voyager Therapeutics by 41.8% in the second quarter. Bank of New York Mellon Corp now owns 33,275 shares of the company’s stock worth $365,000 after buying an additional 9,803 shares during the last quarter. Institutional investors own 39.66% of the company’s stock.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company is focused on developing life-changing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s product pipeline includes programs for Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia, Huntington’s disease, spinal muscular atrophy (SMA), frontotemporal dementia, Alzheimer’s disease and severe, chronic pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.